Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients
Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients: a Triple Blinded, Randomized Controlled Trial to Assess the Efficacy of Tranexamic Acid for Hemostasis
Second Affiliated Hospital, School of Medicine, Zhejiang University
150 participants
Dec 1, 2023
INTERVENTIONAL
Conditions
Summary
Massive blood loss occurs in metastatic spinal tumor resection and may cause severe complications. The objective of this study is to investigate whether the use of tranexamic acid will reduce perioperative and postoperative bleeding when compared to those without use of tranexamic acid.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
IV drip of 2 bottles of tranexamic acid (2g) before making incision during surgery; 1g tranexamic acid soaked gauze applied to the wound for 5 minintes before suture; patients were administered IV drip of tranexamic acid 3 times (every 8 hours)within 24 hours after surgery.
IV drip of 2 bottles of saline before making incision during surgery; saline soaked gauze applied to the wound for 5 minintes before suture; patients were administered IV drip of saline 3 times (every 8 hours)within 24 hours after surgery.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06023212